Literature DB >> 31785185

Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient-, Physician-, Imaging-, and Laboratory-Based Assessments.

Casey A Rimland1, Kaitlin A Quinn2, Joel S Rosenblum3, Mollie N Schwartz3, K Bates Gribbons3, Elaine Novakovich3, Antoine G Sreih4, Peter A Merkel4, Mark A Ahlman3, Peter C Grayson3.   

Abstract

OBJECTIVE: To assess the relationship between measures of disease assessment in patients with large vessel vasculitis.
METHODS: Patients with giant cell arteritis (GCA) or Takayasu arteritis (TAK) were recruited into a prospective, observational cohort. Assessments within the following outcomes were independently recorded: 1) patient-reported outcomes (Multidimensional Fatigue Inventory, patient global assessment of disease activity [PtGA], Short Form 36 health survey [SF-36], Brief Illness Perception Questionnaire), 2) physician global assessment of disease activity (PhGA), 3) laboratory outcomes (C-reactive protein [CRP] level, erythrocyte sedimentation rate [ESR]), and 4) imaging outcomes (PETVAS, a qualitative score of vascular 18 F-fluorodeoxyglucose-positron emission tomography activity).
RESULTS: Analyses were performed on 112 patients (GCA = 56, TAK = 56), over 296 visits, with a median follow-up of 6 months. Correlation network analysis revealed assessment measures clustered independently by type of outcome. PhGA was centrally linked to all other outcome types, but correlations were modest (ρ = 0.12-0.32; P < 0.05). PETVAS, CRP level, and PtGA were independently associated with clinically active disease. All 4 patient-reported outcomes strongly correlated with each other (ρ = 0.35-0.60; P < 0.0001). Patient-reported outcomes were not correlated with PETVAS, and only PtGA correlated with CRP level (ρ = 0.16; P < 0.01). Patients whose clinical assessment changed from active disease to remission (n = 29) had a corresponding significant decrease in ESR, CRP level, and PETVAS at the remission visit. Patients whose clinical assessment changed from remission to active disease (n = 11) had a corresponding significant increase in CRP level and PtGA at the active visit.
CONCLUSION: Measures of disease assessment in large vessel vasculitis consist of independent, yet complementary, outcomes, supporting the need to develop composite outcome measures or a standard set of measures covering multiple types of outcomes.
© 2019, American College of Rheumatology. This article has been contributed to by US Government employees and their work is in the public domain in the USA.

Entities:  

Mesh:

Year:  2020        PMID: 31785185      PMCID: PMC7260082          DOI: 10.1002/acr.24117

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   5.178


  29 in total

1.  Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis.

Authors:  Tanaz A Kermani; Jean Schmidt; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Eric L Matteson; Kenneth J Warrington
Journal:  Semin Arthritis Rheum       Date:  2011-11-25       Impact factor: 5.532

2.  A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis.

Authors:  Carol A Langford; David Cuthbertson; Steven R Ytterberg; Nader Khalidi; Paul A Monach; Simon Carette; Philip Seo; Larry W Moreland; Michael Weisman; Curry L Koening; Antoine G Sreih; Robert Spiera; Carol A McAlear; Kenneth J Warrington; Christian Pagnoux; Kathleen McKinnon; Lindsy J Forbess; Gary S Hoffman; Renée Borchin; Jeffrey P Krischer; Peter A Merkel
Journal:  Arthritis Rheumatol       Date:  2017-03-08       Impact factor: 10.995

Review 3.  Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12.

Authors:  Sibel Zehra Aydin; Haner Direskeneli; Antoine Sreih; Fatma Alibaz-Oner; Ahmet Gul; Sevil Kamali; Gulen Hatemi; Tanaz Kermani; Sarah L Mackie; Alfred Mahr; Alexa Meara; Nataliya Milman; Heidi Nugent; Joanna Robson; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2015-06-15       Impact factor: 4.666

4.  Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise.

Authors:  Sibel Z Aydin; Haner Direskeneli; Peter A Merkel
Journal:  J Rheumatol       Date:  2017-09-01       Impact factor: 4.666

5.  Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial.

Authors:  Peter M Villiger; Sabine Adler; Stefan Kuchen; Felix Wermelinger; Diana Dan; Veronika Fiege; Lukas Bütikofer; Michael Seitz; Stephan Reichenbach
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

6.  Quality of life of patients with Takayasu's arteritis.

Authors:  Christopher J Abularrage; Mark B Slidell; Anton N Sidawy; Peter Kreishman; Richard L Amdur; Subodh Arora
Journal:  J Vasc Surg       Date:  2008-01       Impact factor: 4.268

7.  Coping strategies and depressiveness in primary systemic vasculitis--what is their impact on health-related quality of life?

Authors:  Petra Brezinova; Matthias Englbrecht; Svjetlana Lovric; Alexander Sämann; Bernhard Strauss; Gunter Wolf; Georg Schett; Marion Haubitz; Thomas Neumann; Jochen Zwerina
Journal:  Rheumatology (Oxford)       Date:  2013-07-10       Impact factor: 7.580

8.  Trial of Tocilizumab in Giant-Cell Arteritis.

Authors:  John H Stone; Katie Tuckwell; Sophie Dimonaco; Micki Klearman; Martin Aringer; Daniel Blockmans; Elisabeth Brouwer; Maria C Cid; Bhaskar Dasgupta; Juergen Rech; Carlo Salvarani; Georg Schett; Hendrik Schulze-Koops; Robert Spiera; Sebastian H Unizony; Neil Collinson
Journal:  N Engl J Med       Date:  2017-07-27       Impact factor: 91.245

9.  Psychometric Properties of Three Fatigue Rating Scales in Individuals With Late Effects of Polio.

Authors:  Jan Lexell; Stina B Jonasson; Christina Brogardh
Journal:  Ann Rehabil Med       Date:  2018-10-31

10.  Further validation of the Multidimensional Fatigue Inventory in a US adult population sample.

Authors:  Jin-Mann S Lin; Dana J Brimmer; Elizabeth M Maloney; Ernestina Nyarko; Rhonda Belue; William C Reeves
Journal:  Popul Health Metr       Date:  2009-12-15
View more
  2 in total

Review 1.  Large-vessel vasculitis.

Authors:  Dan Pugh; Maira Karabayas; Neil Basu; Maria C Cid; Ruchika Goel; Carl S Goodyear; Peter C Grayson; Stephen P McAdoo; Justin C Mason; Catherine Owen; Cornelia M Weyand; Taryn Youngstein; Neeraj Dhaun
Journal:  Nat Rev Dis Primers       Date:  2022-01-06       Impact factor: 65.038

2.  Physician Global Assessment as a Disease Activity Measure for Relapsing Polychondritis.

Authors:  Emily Rose; Marcela A Ferrada; Kaitlin A Quinn; Wendy Goodspeed; Laurent Arnaud; Aman Sharma; Hajime Yoshifuji; Jeff Kim; Clint Allen; Arlene Sirajuddin; Marcus Chen; Peter C Grayson
Journal:  Arthritis Care Res (Hoboken)       Date:  2022-04-29       Impact factor: 5.178

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.